Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease.
A growing body of evidence suggests that axonal loss and neurodegeneration are responsible for the permanent neurological deficit that typically develops in the course of MS. To investigate the neurodegenerative component of MS pathogenesis, we examined the expression of alpha-synuclein, a protein whose accumulation is common to many neurodegenerative disorders, under conditions of immune-mediated inflammatory demyelination. alpha-Synuclein expression was examined in the spinal cord of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) in rats using immunofluorescence and in situ hybridization and in postmortem tissues from cases of secondary progressive MS using immunohistochemistry. alpha-Synuclein upregulation was detected in neurons and glia in and close by lesions and in normal appearing spinal cord EAE tissue at the protein and mRNA levels. alpha-Synuclein positive neurons and glia appeared early, and their number was maximal during EAE exacerbations, but some expression was maintained throughout the course of EAE. In addition, increased alpha-synuclein expression was detected in neurons and glia in and close to MS lesions. Although the increased expression of alpha-synuclein was detected as a granular cytoplasmic labeling rather than inclusion bodies, this result does suggest that neuronal cell death in immune-mediated demyelinating disease may share some common features with other neurodegenerative conditions.
Papadopoulos
Dimitrios
D
Department of Cellular and Molecular Neuroscience, Division of Neuroscience, Imperial College Faculty of Medicine, Charing Cross Hospital Campus, Fulham Palace Road, London W6 8RF, UK.
Ewans
Lisa
L
Pham-Dinh
Danielle
D
Knott
Johanna
J
Reynolds
Richard
R
D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D051379:Mice; D009103:Multiple Sclerosis / Q000378:metabolism; D004676:Myelin Basic Protein / Q000378:metabolism; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology / Q000633:toxicity; D063308:Myelin-Oligodendrocyte Glycoprotein; D009457:Neuroglia / Q000166:cytology / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D010525:Peripheral Nerves / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D051381:Rats; D011994:Recombinant Proteins / Q000276:immunology / Q000633:toxicity; D013116:Spinal Cord / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D015854:Up-Regulation; D051844:alpha-Synuclein / Q000235:genetics / Q000378:metabolism*
C571326:MOG protein, human; C571327:Mog protein, mouse; C571328:Mog protein, rat; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D011994:Recombinant Proteins; D051844:alpha-Synuclein